Your browser doesn't support javascript.
loading
Bioactivation and reactivity research advances - 2021 year in review.
Jackson, Klarissa D; Argikar, Upendra A; Cho, Sungjoon; Crouch, Rachel D; Driscoll, James P; Heck, Carley J S; King, Lloyd; Maw, Hlaing Holly; Miller, Grover P; Seneviratne, Herana Kamal; Wang, Shuai; Wei, Cong; Zhang, Donglu; Khojasteh, S Cyrus.
Afiliação
  • Jackson KD; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA.
  • Argikar UA; Non-Clinical Development, Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA.
  • Cho S; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USA.
  • Crouch RD; Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, Nashville, TN, USA.
  • Driscoll JP; Department of Drug Metabolism and Pharmacokinetics, Bristol Myers Squibb, Brisbane, CA, USA.
  • Heck CJS; Medicine Design, Pfizer Worldwide Research, Development and Medical, Groton, CT, USA.
  • King L; Department of DMPK, UCB Biopharma UK, Slough, UK.
  • Maw HH; Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
  • Miller GP; Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Seneviratne HK; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Wang S; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USA.
  • Wei C; Drug Metabolism & Pharmacokinetics, Biogen Inc., Cambridge, MA, USA.
  • Zhang D; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USA.
  • Khojasteh SC; Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., South San Francisco, CA, USA.
Drug Metab Rev ; 54(3): 246-281, 2022 08.
Article em En | MEDLINE | ID: mdl-35876116
ABSTRACT
This year's review on bioactivation and reactivity began as a part of the annual review on biotransformation and bioactivation led by Cyrus Khojasteh (see references). Increased contributions from experts in the field led to the development of a stand alone edition for the first time this year focused specifically on bioactivation and reactivity. Our objective for this review is to highlight and share articles which we deem influential and significant regarding the development of covalent inhibitors, mechanisms of reactive metabolite formation, enzyme inactivation, and drug safety. Based on the selected articles, we created two sections (1) reactivity and enzyme inactivation, and (2) bioactivation mechanisms and safety (Table 1). Several biotransformation experts have contributed to this effort from academic and industry settings.[Table see text].
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Microssomos Hepáticos Limite: Humans Idioma: En Revista: Drug Metab Rev Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Microssomos Hepáticos Limite: Humans Idioma: En Revista: Drug Metab Rev Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos